Xuejiao Xie1, Wenhong Wu1, Ludong Liang1, Shuai Han1, Ting Chen2, Shangling Pan3, Meijuan Xue1, Shikang Li1. 1. Department of Thoracic and Cardiovascular Surgery, The First Affiliated Hospital of Guangxi Medical University Nanning, China. 2. Department of Management Information System, College of Computer and Information Engineering, Guangxi Teachers Education University Nanning, China. 3. Department of Pathophysiology, Guangxi Medical University Nanning, China.
Abstract
BACKGROUND: MicroRNA (miRNA) expressive alterations are associated with cancer and have potential diagnostic and prognostic values in various malignancies. Here, we summarize the global predictive role of miR-210 expression for survival in patients with a variety of carcinomas. METHODS: Eligible studies were identified through multiple search strategies. Data were assembled from studies investigating the relationship between miR-210 expression and survival in cancer patients. Hazard ratio (HR) was used as the common measure of association across studies: relative risk (RR) was considered equivalent to HR. Combined hazard ratios (HRs) of miR-210 for outcome were analyzed. RESULTS: A total of 10 studies dealing with various carcinomas were included for this global meta-analysis. For overall survival (OS), the pooled hazard ratio (HR) of higher miR-210 expression in cancerous tissue was 2.41 (95% CI: 1.31-4.44), which could significantly predict poorer survival in general carcinomas. For distant-free, relapse-free or progressive-free survival, elevated miR-210 was also a significant predictor, with a pooled HR of 2.84 (95% CI: 2.10-3.83). Importantly, subgroup analysis suggested that higher expression of miR-210 correlated with worse OS in breast cancer: HR 4.34, 95% CI: 1.63-11.55. CONCLUSIONS: Our findings reveal that miR-210 detection has a prognostic value in patients with cancer, especially in breast cancer.
BACKGROUND: MicroRNA (miRNA) expressive alterations are associated with cancer and have potential diagnostic and prognostic values in various malignancies. Here, we summarize the global predictive role of miR-210 expression for survival in patients with a variety of carcinomas. METHODS: Eligible studies were identified through multiple search strategies. Data were assembled from studies investigating the relationship between miR-210 expression and survival in cancerpatients. Hazard ratio (HR) was used as the common measure of association across studies: relative risk (RR) was considered equivalent to HR. Combined hazard ratios (HRs) of miR-210 for outcome were analyzed. RESULTS: A total of 10 studies dealing with various carcinomas were included for this global meta-analysis. For overall survival (OS), the pooled hazard ratio (HR) of higher miR-210 expression in cancerous tissue was 2.41 (95% CI: 1.31-4.44), which could significantly predict poorer survival in general carcinomas. For distant-free, relapse-free or progressive-free survival, elevated miR-210 was also a significant predictor, with a pooled HR of 2.84 (95% CI: 2.10-3.83). Importantly, subgroup analysis suggested that higher expression of miR-210 correlated with worse OS in breast cancer: HR 4.34, 95% CI: 1.63-11.55. CONCLUSIONS: Our findings reveal that miR-210 detection has a prognostic value in patients with cancer, especially in breast cancer.
Authors: Thomas Greither; Lukasz F Grochola; Andrej Udelnow; Christine Lautenschläger; Peter Würl; Helge Taubert Journal: Int J Cancer Date: 2010-01-01 Impact factor: 7.396
Authors: Jen-Tsan Chi; Zhen Wang; Dimitry S A Nuyten; Edwin H Rodriguez; Marci E Schaner; Ali Salim; Yun Wang; Gunnar B Kristensen; Aslaug Helland; Anne-Lise Børresen-Dale; Amato Giaccia; Michael T Longaker; Trevor Hastie; George P Yang; Marc J van de Vijver; Patrick O Brown Journal: PLoS Med Date: 2006-03 Impact factor: 11.069
Authors: Ines Block; Mark Burton; Kristina P Sørensen; Lars Andersen; Martin J Larsen; Martin Bak; Søren Cold; Mads Thomassen; Qihua Tan; Torben A Kruse Journal: Oncotarget Date: 2018-01-09
Authors: LaShanale Wallace; Karen Aikhionbare; Saswati Banerjee; Katie Peagler; Mareena Pitts; Xuebiao Yao; Felix Aikhionbare Journal: Cancer Res J (N Y N Y) Date: 2021-01-25
Authors: Antonina Parafioriti; Caterina Bason; Elisabetta Armiraglio; Lucia Calciano; Primo Andrea Daolio; Martina Berardocco; Andrea Di Bernardo; Alessia Colosimo; Roberto Luksch; Anna C Berardi Journal: Int J Mol Sci Date: 2016-04-30 Impact factor: 5.923